drugset / Trial / NCT07679360
A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
It is a randomized, open label, positive drug controlled, multicenter design Phase III clinical trial, aims to compare the efficacy and safety of SHR-A1811 combined with Adebrelimab and the treatment selected by the researchers in the adjuvant treatment of triple negative breast cancer with invasive residual cancer after neoadjuvant treatment, and to explore the PK characteristics and immunogenicity of SHR-A1811 and Adebrelimab.
Timeline
- Start
- 2026-07
- Primary completion
- 2030-12
- Completion
- 2032-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebrelimab | Monoclonal antibody | — | — |
| Comparator | Capecitabine | Small molecule | — | — |
| Comparator | Pembrolizumab | Monoclonal antibody | — | — |
| Subject | Trastuzumab Rezetecan | Monoclonal antibody | — | — |